Page last updated: 2024-11-05

thalidomide and Cytokine Release Syndrome

thalidomide has been researched along with Cytokine Release Syndrome in 3 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.

Research Excerpts

ExcerptRelevanceReference
"There is no agreed treatment for cytokine storm."1.56Alternative management of Covid-19 infection. ( Atrah, HI, 2020)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's3 (100.00)2.80

Authors

AuthorsStudies
Atrah, HI1
Talamonti, M1
Tofani, L1
Bianchi, L1
Galluzzo, M1
Shah, CA1

Other Studies

3 other studies available for thalidomide and Cytokine Release Syndrome

ArticleYear
Alternative management of Covid-19 infection.
    Scottish medical journal, 2020, Volume: 65, Issue:3

    Topics: Administration, Intravenous; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatm

2020
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?
    Archives of dermatological research, 2021, Volume: 313, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Biological Factors; Clinical Decision-Making; Comorbidity;

2021
Can roflumilast become steroid-sparing alternative in the treatment of COVID-19?
    Medical hypotheses, 2020, Volume: 144

    Topics: Adrenal Cortex Hormones; Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; COVID-19 Dru

2020